Introduction
When a biotech company finally wins FDA approval for a groundbreaking drug, the natural expectation is that its stock will soar. But markets aren't always logical—as Milestone Pharmaceuticals (NASDAQ: MIST) demonstrated on a recent Wednesday. Despite receiving FDA approval for Cardamyst, its first-ever approved product, the stock slumped more than 9% after the company released its quarterly earnings and business update. This counterintuitive move can confuse even seasoned investors. In this step-by-step guide, you'll learn how to dissect such a situation—using the Milestone case as a real-world example—so you can better evaluate biotech stocks and avoid costly misinterpretations.
What You Need
- Access to the company's latest earnings report and business update (e.g., from SEC filings or investor relations page)
- A stock chart showing the day's price movement (e.g., from Yahoo Finance or Bloomberg)
- Basic understanding of the drug's indication (here: paroxysmal supraventricular tachycardia or PSVT)
- Knowledge of the FDA approval process and what 'first approval' means for a company
- Internet connection to research analyst reports and news articles
- A notebook or digital document to record observations
Step-by-Step Guide
Step 1: Identify the Trigger Event(s)
The first step is to pinpoint exactly what caused the stock to drop. In Milestone's case, the trigger was not the FDA approval itself (which happened months earlier in December) but the quarterly earnings report and business update released on that Wednesday. Did the company miss revenue expectations? Did it announce a setback? Check the press release: Milestone's Q1 was historic because of Cardamyst—its first approved drug—yet the market sold off. This tells you that the approval was already priced in, and investors were looking at other factors.
Step 2: Examine the Financial and Operational Details
Now dive into the numbers. In a biotech without prior sales, revenue often comes from partnerships, grants, or licensing. Did Milestone report any sales of Cardamyst? Likely minimal because the drug was just approved in December and commercial launch takes time. Check cash burn rate, R&D expenses, and guidance. If the company is spending more than expected or delaying commercialization, the market may react negatively. Also look for non-financial updates: any regulatory hurdles, competitor news, or changes in management. For Milestone, the drop suggests that the earnings report revealed something that disappointed investors relative to their expectations.
Step 3: Evaluate the Market's Reaction vs. Fundamentals
Ask yourself: Is the drop justified by the underlying business? Milestone now has a revenue-generating product (Cardamyst), which is a huge milestone. A 9% drop might be a short-term reaction to profit-taking or a broader market sell-off. Compare the stock's performance to the biotech index or to peers with similar drug launches. Use a price-to-sales or price-to-book ratio if possible, but for pre-revenue biotech, focus on pipeline value and cash position. If the drop seems excessive, it could be a buying opportunity—or a warning that the market sees problems you haven't spotted yet.
Step 4: Look for Hidden Context
Sometimes the real story isn't in the press release. Check earnings call transcripts for forward-looking statements. Did management issue cautious guidance about Cardamyst's adoption? Were there mentions of manufacturing issues, reimbursement challenges, or competitive threats? The original article notes that Cardamyst is a nasal spray for a specific type of rapid heartbeat—PSVT. That's a niche market. If the total addressable market is smaller than analysts expected, that could justify a sell-off. Also consider the timing: the FDA approval was in December, and by the time of the Q1 report, the stock might have already rallied. The drop could be a classic buy the rumor, sell the news event.
Step 5: Synthesize Findings for Investment Decisions
After completing steps 1-4, you should have a clear picture. In Milestone's case: the trigger was a routine earnings update, not bad news about Cardamyst. The drug is its first approved product, but commercial revenue is still nascent. The market likely overreacted due to unmet expectations or profit-taking. For an investor, this could be a chance to buy at a discount if you believe in the drug's long-term potential. Alternatively, if the drop reveals fundamental issues (e.g., slow launch), it might be time to exit. Write down your conclusion and revisit after the next quarterly report to see if your analysis held up.
Tips for Analyzing Similar Situations
- Don't equate volatility with value destruction. Biotech stocks are inherently volatile; a 9% drop on no real news can be noise.
- Always read the full earnings release, not just headlines. The devil is in the footnotes and MD&A (Management Discussion & Analysis).
- Compare the stock's performance 3-6 months before the event. If it already doubled, a pullback may be healthy.
- Understand the drug's market potential. A first approval is exciting, but if the addressable population is small, revenue growth may be slow.
- Monitor insider trading activity. If executives are selling after the drop, that's a red flag.
- Use a watchlist to track subsequent price action. Often the market corrects its initial overreaction within weeks.
- Consult professional analyst reports but form your own opinion based on the data.
By following these steps, you can systematically unpack why a biotech stock like Milestone Pharmaceuticals tumbles after what seems like good news. The key is to separate the emotion from the fundamentals—and to remember that in the long run, it's the science and commercial execution that matter most.